Championing for people with all abilities Championing for people with all abilities Every diverse background brings unique perspectives to our company.
What you need to know about counterfeit medicines What you need to know about counterfeit medicines Understand the risk of counterfeit medication.
Experience our culture during your interview process Experience our culture during your interview process Discover if our company is the right fit for you.
200 employees make a difference with record-breaking volunteer efforts 200 employees make a difference with record-breaking volunteer efforts 200 employees make a difference with record-breaking volunteer efforts
Advocating for More Patient-Centered Mental Health Care Advocating for More Patient-Centered Mental Health Care Advocating for More Patient-Centered Mental Health Care
Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US The FDA granted Breakthrough Therapy designation for JARDIANCE® (empagliflozin) as treatment for HFpEF. View ISI, PI and Med Guide.
When Passion Starts as a Family Value and Continues as a Work Value When Passion Starts as a Family Value and Continues as a Work Value Discover who inspires members of our LatinX Business Resource Group.
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia
Striving to revolutionize mental health research Striving to revolutionize mental health research World Mental Health Day: We are committed to transforming the mental health landscape through precision psychiatry
We support non-linear career paths. We support non-linear career paths. Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
She finds purpose in the saddle and pursues a passion for horses – at home and work She finds purpose in the saddle and pursues a passion for horses – at home and work She finds purpose in the saddle and pursues a passion for horses – at home and work
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
Flying animals to safety with Greater Good Charities Flying animals to safety with Greater Good Charities Watch as Julie Ryan-Johnson volunteers to take care of animals being brought to new homes following the Maui wildfires.
New agreement with Quallent expands biosimilar access New agreement with Quallent expands biosimilar access Boehringer Ingelheim enters private label agreement for biosimilar
Management Rotation | Academic Programs Management Rotation | Academic Programs Management Rotation Program
Romy's Third-generation Japanese American Journey Romy's Third-generation Japanese American Journey Romy's Third-generation Japanese American Journey
Boehringer Ingelheim Medicine Post-Doctoral and Post-PharmD Fellowships Boehringer Ingelheim Medicine Post-Doctoral and Post-PharmD Fellowships Boehringer Ingelheim Medicine Post-Doctoral and Post-PharmD Fellowships
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo. Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo. Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo.
BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.